Antinori, A. et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69, 1789–1799 (2007).
Maschke, M. et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J. Neurol. Neurosurg. Psychiatry. 69, 376–380 (2000).
Elicer, M., Byrd, I., Clark, D., Morgello, U. S., Robinson-Papp, J. & S. & Motor function declines over time in human immunodeficiency virus and is associated with cerebrovascular disease, while HIV-associated neurocognitive disorder remains stable. J. Neurovirol. 24, 514–522 (2018).
Goetz, C. G. et al. Movement disorder Society-sponsored revision of the unified parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170 (2008).
Stebbins, G. T. et al. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified parkinson’s disease rating scale: comparison with the unified parkinson’s disease rating scale. Mov. Disord. 28, 668–670 (2013).
Kumar, A. M., Ownby, R. L., Waldrop-Valverde, D., Fernandez, B. & Kumar, M. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J. Neurovirol. 17, 26–40 (2011).
Nickoloff-Bybel, E. A., Calderon, T. M., Gaskill, P. J. & Berman, J. W. HIV neuropathogenesis in the presence of a disrupted dopamine system. J. Neuroimmune Pharmacol. 15, 729–742 (2020).
Kumar, A. M. et al. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J. Neurovirol. 15, 257–274 (2009).
Gaskill, P. J., Miller, D. R., Gamble-George, J., Yano, H. & Khoshbouei, H. HIV, Tat and dopamine transmission. Neurobiol. Dis. 105, 51–73 (2017).
Vázquez-Santiago, F. J., Noel, R. J. & Porter, J. T. Rivera-Amill, V. Glutamate metabolism and HIV-associated neurocognitive disorders. J. Neurovirol. 20, 315–331 (2014).
Saylor, D. et al. HIV-associated neurocognitive disorder–pathogenesis and prospects for treatment. Nat. Rev. Neurol. 12, 234–248 (2016).
Marino, J., Wigdahl, B., Nonnemacher, M. R. & Extracellular HIV-1 Tat mediates increased glutamate in the CNS leading to onset of senescence and progression of HAND. Front. Aging Neurosci. 12, 168 (2020).
Koutsilieri, E. et al. Brain choline acetyltransferase reduction in SIV infection. An index of early dementia? Neuroreport 11, 2391–2393 (2000).
Kamkwalala, A. & Newhouse, P. Mechanisms of cognitive aging in the HIV-Positive adult. Curr. Behav. Neurosci. Rep. 4, 188–197 (2017).
Balcom, E. F., Roda, W. C., Cohen, E. A., Li, M. Y. & Power, C. HIV-1 persistence in the central nervous system: viral and host determinants during antiretroviral therapy. Curr. Opin. Virol. 38, 54–62 (2019).
Ensoli, B. et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67, 277–287 (1993).
Rayne, F. et al. Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J. 29, 1348–1362 (2010).
Cafaro, A. et al. Role of HIV-1 Tat protein interactions with host receptors in HIV infection and pathogenesis. Int. J. Mol. Sci. 25, 1704 (2024).
Albini, A. et al. HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. U S A. 95, 13153–13158 (1998).
Westendorp, M. O. et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375, 497–500 (1995).
Shmakova, A. et al. HIV-1 Tat is present in the serum of people living with HIV-1 despite viral suppression. Int. J. Infect. Dis. 142, 106994 (2024).
Chun, T. W. et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115, 3250–3255 (2005).
Dahl, V. et al. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS 28, 2251–2258 (2014).
Edén, A. et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J. Infect. Dis. 202, 1819–1825 (2010).
Ferretti, F., Gisslen, M., Cinque, P. & Price, R. W. Cerebrospinal fluid HIV escape from antiretroviral therapy. Curr. HIV/AIDS Rep. 12, 280–288 (2015).
Hatano, H. et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24, 2535–2539 (2010).
Palmer, S. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U S A. 105, 3879–3884 (2008).
Jamal Eddine, J. et al. HIV transcription persists in the brain of virally suppressed people with HIV. PLoS Pathog. 20, e1012446 (2024).
Henderson, L. J. et al. Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy. AIDS 33 (Suppl 2), S145–S157 (2019).
Haughey, N. J., Holden, C. P., Nath, A. & Geiger, J. D. Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein Tat. J. Neurochem. 73, 1363–1374 (1999).
Nath, A., Conant, K., Chen, P., Scott, C. & Major, E. O. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J. Biol. Chem. 274, 17098–17102 (1999).
Agrawal, L., Louboutin, J. P., Reyes, B. A. S., Van Bockstaele, E. J. & Strayer, D. S. HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. Neurobiol. Dis. 45, 657–670 (2012).
Zauli, G. et al. HIV-1 Tat-mediated Inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J. Biol. Chem. 275, 4159–4165 (2000).
Miller, D. R. et al. HIV-1 Tat regulation of dopamine transmission and microglial reactivity is brain region specific. Glia 66, 1915–1928 (2018).
Yuan, Y. et al. Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter. ACS Chem. Neurosci. 6, 658–665 (2015).
Quizon, P. M. et al. Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat protein-inhibited dopamine transport. Sci. Rep. 6, 39048 (2016).
Adeniran, C. et al. Binding mode of human norepinephrine transporter interacting with HIV-1 Tat. ACS Chem. Neurosci. 12, 1519–1527 (2021).
Bachani, M., Sacktor, N., McArthur, J. C., Nath, A. & Rumbaugh, J. Detection of anti-tat antibodies in CSF of individuals with HIV-associated neurocognitive disorders. J. Neurovirol. 19, 82–88 (2013).
Ensoli, B. et al. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology 13, 34 (2016).
Sgadari, C. et al. Continued decay of HIV proviral DNA upon vaccination with HIV-1 Tat of subjects on Long-Term ART: an 8-Year Follow-Up study. Front. Immunol. 10, 233 (2019).
Ensoli, F. et al. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology 12, 33 (2015).
Butters, N. et al. Assessment of AIDS-related cognitive changes: recommendations of the NIMH workshop on neuropsychological assessment approaches. J. Clin. Exp. Neuropsychol. 12, 963–978 (1990).
Blackstone, K. et al. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin. Neuropsychol. 26, 894–908 (2012).
Henderson, L. J., Sharma, A., Monaco, M. C. G., Major, E. O. & Al-Harthi, L. Human immunodeficiency virus type 1 (HIV-1) transactivator of transcription through its intact core and cysteine-rich domains inhibits Wnt/β-catenin signaling in astrocytes: relevance to HIV neuropathogenesis. J. Neurosci. 32, 16306–16313 (2012).
Rempel, H. C. & Pulliam, L. HIV-1 Tat inhibits Neprilysin and elevates amyloid beta. AIDS Lond. Engl. 19, 127–135 (2005).
Aksenov, M. Y., Aksenova, M. V., Mactutus, C. F. & Booze, R. M. Attenuated neurotoxicity of the transactivation-defective HIV-1 Tat protein in hippocampal cell cultures. Exp. Neurol. 219, 586–590 (2009).
Bertrand, S. J., Aksenova, M. V., Mactutus, C. F. & Booze, R. M. HIV-1 Tat protein variants: critical role for the cysteine region in synaptodendritic injury. Exp. Neurol. 248, 228–235 (2013).
Mishra, M., Vetrivel, S., Siddappa, N. B., Ranga, U. & Seth, P. Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann. Neurol. 63, 366–376 (2008).
Agan, B. K. et al. The US military HIV natural history study: informing military HIV care and policy for over 30 years. Mil Med. 184, 6–17 (2019).
Zhu, J., Ananthan, S. & Zhan, C. G. The role of human dopamine transporter in neuroaids. Pharmacol. Ther. 183, 78–89 (2018).
Brorson, J. R., Manzolillo, P. A. & Miller, R. J. Ca2 + entry via AMPA/KA receptors and excitotoxicity in cultured cerebellar purkinje cells. J. Neurosci. 14, 187–197 (1994).
Nath, A. et al. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J. Virol. 70, 1475–1480 (1996).
Krone, W. J. et al. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J. Med. Virol. 26, 261–270 (1988).
Reiss, P. et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J. Med. Virol. 30, 163–168 (1990).
Rezza, G. et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J. Infect. Dis. 191, 1321–1324 (2005).
Re, M. C. et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J. Clin. Virol. 21, 81–89 (2001).
Nicoli, F. et al. Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort. BMC Infect. Dis. 16, 344 (2016).
Tripiciano, A. et al. Anti-Tat immunity defines CD4 + T-cell dynamics in people living with HIV on long-term cART. EBioMedicine 66, 103306 (2021).
Caselli, E. et al. DNA immunization with HIV-1 Tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J. Immunol. 1950. 162, 5631–5638 (1999).
Aldovini, A. et al. Synthesis of the complete trans-activation gene product of human T-lymphotropic virus type III in Escherichia coli: demonstration of immunogenicity in vivo and expression in vitro. Proc. Natl. Acad. Sci. U S A. 83, 6672–6676 (1986).
Tomusange, K. et al. A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly Immunogenic and contains acute ecohiv infection in mice. Sci. Rep. 6, 29131 (2016).
Karasev, A. V. et al. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach. Vaccine 23, 1875–1880 (2005).
Cafaro, A. et al. Anti-Tat immunity in HIV-1 infection: effects of naturally occurring and Vaccine-Induced antibodies against Tat on the course of the disease. Vaccines 7, 99 (2019).
Ensoli, B. et al. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 28, 371–378 (2009).
Longo, O. et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 27, 3306–3312 (2009).
Bansal, A. K. et al. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res. 879, 42–49 (2000).
Bezzi, P. et al. CXCR4-activated astrocyte glutamate release via tnfalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci. 4, 702–710 (2001).
Jones, G. J. et al. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J. Neurosci. 27, 3703–3711 (2007).
Yang, J. et al. HIV-1 Vpu induces neurotoxicity by promoting caspase 3-dependent cleavage of TDP-43. EMBO Rep. 25, 4337–4357 (2024).
van Marle, G. et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 329, 302–318 (2004).
Kashi, V. P. et al. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently. Vaccine 27, 6739–6747 (2009).
Robinson-Papp, J. et al. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort. Arch. Neurol. 65, 1096–1101 (2008).
Balasubramanian, P. et al. Functional antibody response against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 vaccine trials. Sci. Rep. 8, 542 (2018).
